Identification of midkine as a mediator for intercellular transfer of drug resistance.
Resistance to cytotoxic agents is a major limitation for their clinical use to treat human cancers. Tumors become resistant to chemotherapy when a subset of cells undergoes molecular changes leading to overexpression of drug transport proteins, alterations in drug-target interactions or reduced ability to commit apoptosis. However, such changes may not be sufficient to explain why both resistant and nonresistant cells survive drug's action in tumors that ultimately become drug resistant. We hypothesized that, in such tumors, a cytoprotective relationship may exist between drug-resistant and neighboring drug-sensitive cells. The present study addresses the possibility that drug-resistant cells secrete in their culture medium factors able to protect sensitive cells from drug toxicity. A survival molecule, midkine, was identified by cDNA array to be expressed only in drug-resistant cells. Midkine-enriched fractions obtained by affinity chromatography exert a significant cytoprotective effect against doxorubicin in the wild-type drug-sensitive cells. Moreover, transfection of these cells with the midkine gene caused a decreased response to doxorubicin. The underlying mechanism of this cytoprotection appeared to imply activation of the Akt pathway and inhibition of drug-induced proliferation arrest as well as apoptotic cell death. These findings provide evidence for the existence of intercellular cytoprotective signals such as the one mediated by midkine, originating from cells with acquired drug resistance to protect neighboring drug-sensitive cells and thus contribute to development of resistance to chemotherapy.
Mirkin
Bernard L
BL
Children's Memorial Research Center (CMRC), Cancer Biology Program, Chicago, IL 60614, USA.
Clark
Sandra
S
Zheng
Xin
X
Chu
Fei
F
White
Bryan D
BD
Greene
Marianne
M
Rebbaa
Abdelhadi
A
D001692:Biological Transport; D002455:Cell Division / Q000502:physiology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D016207:Cytokines / Q000235:genetics / Q000502:physiology*; D004317:Doxorubicin / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm; D006801:Humans; D000078792:Midkine; D009414:Nerve Growth Factors / Q000502:physiology; D009447:Neuroblastoma; D020411:Oligonucleotide Array Sequence Analysis; D014162:Transfection
D016207:Cytokines; D009414:Nerve Growth Factors; D000078792:Midkine; D004317:Doxorubicin